Tag Archives: Dasatinib

Dasatinib can be a therapeutic choice for patients with severe scGVHD resistant or intolerant to imatinib.

Sclerotic chronic graft-versus-host disease (scGVHD) is often a severe form of this disease that resembles systemic sclerosis and has limited and disappointing therapy solutions. Tyrosine kinase inhibitors (TKI) targeting upregulated profibrotic pathways which include imatinib mesylate, have been proposed as … Continue reading

Posted in Uncategorized | Tagged | Leave a comment